Cocoon Bioscience

Executive Summary

Cocoon Bioscience, a Spanish biotech founded in 2019, has developed CrisBio®, a novel recombinant protein expression platform that uses insect chrysalises as natural, automated bioreactors. This approach enables scalable, cost-effective production of complex proteins and enzymes, addressing key bottlenecks in biologics manufacturing. By leveraging the innate machinery of chrysalises, the platform simplifies downstream processing and reduces capital expenditure compared to traditional cell-based systems. The technology is particularly suited for high-value therapeutics, industrial enzymes, and emerging modalities like mRNA-based proteins. The company targets a rapidly growing market for protein expression, estimated to exceed $20B by 2030, driven by demand for biologics and sustainable biomanufacturing. Cocoon's platform offers a differentiated value proposition: lower upfront investment, faster scale-up, and ability to produce difficult-to-express proteins. While still in early stages, the company has likely raised seed funding and is pursuing partnerships with pharma and industrial biotech firms. If successful, CrisBio® could become a disruptive alternative to traditional microbial and mammalian systems, though commercialization risks and regulatory hurdles remain.

Upcoming Catalysts (preview)

• Q3 2026First commercial partnership for CrisBio® platform40% success
• Q4 2026Series A funding round to scale operations60% success
• Q2 2026Publication of proof-of-concept data in peer-reviewed journal70% success